171 related articles for article (PubMed ID: 31435033)
1. Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment.
Rivas MM; Berro M; Prates MV; Yantorno S; Fiad L; Arbelbide JA; Basquiera AL; Ferini GA; García JJ; García PA; Riera L; Jarchum G; Baso A; Real J; Castro M; Jaimovich G; Martinez Rolón J; Foncuberta C; Saba S; Kusminsky G;
Bone Marrow Transplant; 2020 Jan; 55(1):117-125. PubMed ID: 31435033
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.
Spina F; Radice T; De Philippis C; Soldarini M; Di Chio MC; Dodero A; Guidetti A; Viviani S; Corradini P
Leuk Lymphoma; 2019 Jan; 60(1):101-109. PubMed ID: 29716416
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
4. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Sirohi B; Cunningham D; Powles R; Murphy F; Arkenau T; Norman A; Oates J; Wotherspoon A; Horwich A
Ann Oncol; 2008 Jul; 19(7):1312-1319. PubMed ID: 18356139
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients.
Castagna L; Busca A; Bramanti S; Raiola Anna M; Malagola M; Ciceri F; Arcese W; Vallisa D; Patriarca F; Specchia G; Raimondi R; Devillier R; Furst S; Giordano L; Sarina B; Mariotti J; Olivieri A; Bouabdallah R; Carlo-Stella C; Rambaldi A; Santoro A; Corradini P; Bacigalupo A; Bonifazi F; Blaise D
BMC Cancer; 2020 Nov; 20(1):1140. PubMed ID: 33234127
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability.
Sarina B; Castagna L; Farina L; Patriarca F; Benedetti F; Carella AM; Falda M; Guidi S; Ciceri F; Bonini A; Ferrari S; Malagola M; Morello E; Milone G; Bruno B; Mordini N; Viviani S; Levis A; Giordano L; Santoro A; Corradini P;
Blood; 2010 May; 115(18):3671-7. PubMed ID: 20220116
[TBL] [Abstract][Full Text] [Related]
8. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660
[TBL] [Abstract][Full Text] [Related]
10. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
11. Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT.
Martínez C; Boumendil A; Romejko-Jarosinska J; Anagnostopoulos A; Faber E; Poiré X; Yakoub-Agha I; Akhtar S; Gurman G; Pavone V; Halaburda K; Sousa AB; Ghesquières H; Finel H; Khvedelidze I; Montoto S; Sureda A
Leuk Lymphoma; 2020 Dec; 61(12):2915-2922. PubMed ID: 32654552
[TBL] [Abstract][Full Text] [Related]
12. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
[TBL] [Abstract][Full Text] [Related]
14. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2020 Dec; 99(12):2911-2925. PubMed ID: 33000361
[TBL] [Abstract][Full Text] [Related]
15. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience.
Roerden M; Sökler M; Kanz L; Bethge W; Vogel W; Walz JS
Ann Hematol; 2020 Feb; 99(2):265-276. PubMed ID: 31897675
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
[TBL] [Abstract][Full Text] [Related]
17. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
18. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
19. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
[TBL] [Abstract][Full Text] [Related]
20. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
